Market capitalization | $29.83m |
Enterprise Value | $52.84m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 15.92 |
EV/Sales (TTM) EV/Sales | 7.43 |
P/S ratio (TTM) P/S ratio | 4.20 |
P/B ratio (TTM) P/B ratio | 8.08 |
Revenue growth (TTM) Revenue growth | -36.30% |
Revenue (TTM) Revenue | $7.11m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | 7.11 7.11 |
36%
36%
|
|
Gross Profit | -0.34 -0.34 |
118%
118%
|
|
EBITDA | -3.95 -3.95 |
152%
152%
|
EBIT (Operating Income) EBIT | -7.77 -7.77 |
166%
166%
|
Net Profit | -17 -17 |
18%
18%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
JanOne, Inc. focuses on finding treatments for conditions that cause severe pain and markets drugs with non-addictive pain-relieving properties. It operates through the following segments: Biotechnology, Recycling and Technology. The Recycling segment is a turnkey appliance recycling program. The Biotechnology segment deals in the development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The Technology segment develops technology to enable low cost, location-based products and services. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.
Head office | United States |
CEO | Peter Tassiopoulos |
Employees | 5 |
Founded | 1976 |
Website | www.alt5sigma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.